# CERebrolysin In CADASIL

> **NCT05755997** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ever Neuro Pharma GmbH** · enrollment: 30 (estimated)

## Conditions studied

- Cadasil

## Interventions

- **DRUG:** Cerebrolysin
- **DRUG:** 0.9 % NaCl

## Key facts

- **NCT ID:** NCT05755997
- **Lead sponsor:** Ever Neuro Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-29
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05755997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05755997, "CERebrolysin In CADASIL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05755997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*